Elekta Nets CE Mark for AI-Powered Elekta Evo CT-Linac

Elekta announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo, has received CE mark and is available for sale and marketing in Europe. Offering offline and online plan adaptation, as well as improved image-guided radiation therapy (IGRT) treatments, Evo enables clinicians to choose the most suitable radiation therapy technique for each cancer patient’s individual case or treatment session.

“With Evo, we are emphasizing flexibility regarding how and when clinics want to implement adaptive radiation therapy (ART),” says Maurits Wolleswinkel, Elekta’s President Linac and Software Solutions. “Some may prefer to continue their high throughput IGRT service and use ART for select cases and adapt plans when needed, all in one machine. Evo’s range of techniques and the ability to adopt new treatments at a pace that suits a clinicians’ needs have shown positive responses from our clinical research partners.”

When delivering radiation therapy, clinicians require high-quality images that enable them to visualize tumors and organs at risk to facilitate contouring. Evo addresses this need with two essential features: Iris high-definition, AI-enhanced imaging which allows clinicians to visualize target areas with greater clarity, and Elekta ONE Online integrated on the linac,  which brings distributed treatment planning, faster dose calculation and AI-driven automation for contouring and dose planning.

Gustaf Salford, Elekta’s CEO, said, “With Evo, we are making personalized, clinically effective adaptive radiation therapy treatments available to more patients. We have seen great interest in Evo from our customers and we will start installing in the coming quarters.”